Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34450
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18056/20254 (89%)
Visitors : 508428      Online Users : 543
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34450


    Title: Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
    Authors: Liou, Bo-Huang
    Sun, Hsin-Yun
    Yang, Chia-Jui
    Syue, Ling-Shan
    Lee, Yu-Lin
    Tang, Hung-Jen
    Tsai, Hung-Chin
    Lin, Chi-Ying
    Chen, Tun-Chieh
    Lee, Chun-Yuan
    Huang, Sung-Hsi
    Liu, Chia-Wei
    Lu, Po-Liang
    Lin, Shih-Ping
    Wang, Ning-Chi
    Cheng, Aristine
    Ko, Wen-Chien
    Cheng, Shu-Hsing
    Hung, Chien-Ching
    Contributors: Hsinchu MacKay Mem Hosp, Dept Internal Med
    Natl Taiwan Univ Hosp, Dept Internal Med
    Natl Taiwan Univ, Coll Med
    Natl Yang Ming Univ, Sch Med
    Far Eastern Mem Hosp, Dept Internal Med
    Natl Cheng Kung Univ Hosp, Dept Internal Med
    Natl Cheng Kung Univ, Coll Med
    Changhua Christian Hosp, Dept Internal Med
    Dept Internal Med, Chi Mei Med Ctr
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Kaohsiung Vet Gen Hosp, Dept Internal Med
    Natl Taiwan Univ Hosp, Yunlin Branch, Dept Internal Med, Huwei Township
    Kaohsiung Municipal Tatung Hosp, Dept Internal Med
    Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan;[Chen, Tun-Chieh;Lee, Chun-Yuan;Lu, Po-Liang
    Kaohsiung Med Univ, Coll Med
    Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch
    Natl Taiwan Univ, Dept Trop Med & Parasitol, Coll Med
    Taichung Vet Gen Hosp, Dept Internal Med
    Triserv Gen Hosp, Dept Internal Med
    Natl Def Med Ctr
    Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf
    Taipei Med Univ, Sch Publ Hlth
    Keywords: Antiretroviral therapy
    Direct-acting antivirals
    End-of-treatment response
    Estimated glomerular filtration rate
    Ledipasvir
    Sofosbuvir
    Sustained virologic response
    Date: 2021
    Issue Date: 2023-11-11 11:53:27 (UTC+8)
    Publisher: SPRINGER LONDON LTD
    Abstract: Introduction While coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12 weeks off-therapy (SVR12). Results Of the 114 patients (mean age, 38.6 years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m(2) and were receiving antiretroviral therapy with 98.2% having CD4 counts >= 200 cells/mm(3) and 93.9% plasma HIV RNA load < 50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, - 8.33 ml/min/1.73 m(2)), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2.
    Relation: INFECT DIS THER, v.10, n.2, pp.827-838
    Appears in Collections:[Dept. of Health and Nutrition (including master's program)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML148View/Open
    s40121-021-00424-8.pdf440KbAdobe PDF50View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback